allogeneic natural killer cells
Natural killer cells, also known as NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. They are a kind of large granular lymphocyte (LGL), belong to the rapidly expanding family of known innate lymphoid cells (ILC), and represent 5–20% of all circulating lymphocytes in humans. The role of NK cells is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cells, stressed cells, tumor cells, and other intracellular pathogens based on signals from several activating and inhibitory receptors. Most immune cells detect the antigen presented on major histocompatibility complex I (MHC-I) on infected cell surfaces, but NK cells can recognize and kill stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the notion that they do not require activation to kill cells that are missing "self" markers of MHC class I. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells. — Wikipedia
Clinical trial activity
141 trials · 116 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2001 (NCT01220544)
Timeline
Indications
Studied for
- Abortion, Missed · Phase 2
- Aged · Phase 1/Phase 2
- Antigens, CD19 · Phase 1/Phase 2
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Bone Marrow Cells · Phase 1
- Brain Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 2/Phase 3
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Mucoepidermoid · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- COVID-19 · Phase 1/Phase 2
- Dendritic Cells · Phase 2
- Digestive System Neoplasms · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Drugs, Investigational · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Glioblastoma · Phase 1
- Gliosarcoma · Phase 1
- Graft vs Host Disease · Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 1
- Hematologic Neoplasms · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 1/Phase 2
- HIV · Phase 1
- HIV Infections · Phase 1
- Hodgkin Disease · Phase 2
- Immune System Diseases · Phase 1
- Infertility · Phase 2
- Intestinal Neoplasms · Phase 1
- Kidney Neoplasms · Phase 2
- Killer Cells, Natural · Phase 2
- Leukemia · Phase 2
- Leukemia, Biphenotypic, Acute · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Leukemia, Myelomonocytic, Juvenile · Phase 2
- Leukemia, Plasma Cell · Phase 1/Phase 2
- Liver Neoplasms · Phase 2/Phase 3
- Living Donors · Phase 1/Phase 2
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 1
- Lymphoproliferative Disorders · Phase 1/Phase 2
- Maximum Tolerated Dose · Phase 1/Phase 2
- Melanoma · Phase 2
- Mesothelioma · Phase 1
- Microsatellite Instability · Phase 1
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Myositis · Phase 2
- Nasopharyngeal Carcinoma · Phase 1/Phase 2
- Nasopharyngeal Neoplasms · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasm, Residual · Phase 1/Phase 2
- Neoplasms · Phase 2
- Neuroblastoma · Phase 2
- Organ Transplantation · Phase 1
- Osteosarcoma · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Rectal Neoplasms · Phase 1
- Reproductive Health · Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 1
- Sarcoma, Ewing · Phase 2
- Sarcoma, Myeloid · Phase 2
- Scleroderma, Systemic · Phase 2
- Sclerosis · Phase 2
- Sjogren's Syndrome · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stem Cell Transplantation · Phase 1
- Stomach Neoplasms · Phase 1/Phase 2
- Tongue Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1/Phase 2
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNatural killer cell ↗
Also known as
- allogeneic natural killer cells
- allogeneic nk cells
- allogenic nk cells
- donor natural killer cell
- donor natural killer cells
- donor nk cell
- expanded haploidentical natural killer cells
- expanded nk cells
- haploidentical donor derived natural killer cell
- haploidentical natural killer cell
- haploidentical nk cell
- haploidentical nk cells
- immune killer cells
- natural killer cell
- natural killer cells
- nk cell
- nk cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07247201 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2026 | Singapore General Hospital |
| NCT07225439 | Phase 1 | Dec 31, 2025 | Case Western Reserve University, Incyte |
| NCT07230574 | Phase 2 | Nov 30, 2025 | Anhui Medical University, Nanjing University, Soochow University, University of Science and Technology of China, Zhejiang University |
| NCT06991114 | Phase 2 | Jul 9, 2025 | Artiva Biotherapeutics, Inc. |
| NCT07259889 | Phase 1 | Jun 16, 2025 | Chinese Academy of Medical Sciences, Government of China |
| NCT07044050 | Phase 1 | Jun 10, 2025 | Emmecell |
| NCT07256210 | Phase 2 | May 9, 2025 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
| NCT06751134 | Phase 1 | Dec 28, 2024 | Nanjing Medical University |
| NCT06750133 | Phase 1 | Dec 14, 2024 | Zhejiang University |
| NCT06641648 | Phase 1 | Dec 1, 2024 | Peking University |
| NCT06674265 | Phase 1 | Nov 30, 2024 | Iran University of Medical Sciences, Kian Immune Cell Company, Royan Institute |
| NCT06730009 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2024 | Medigen Biotechnology Corporation |
| NCT06568328 | Phase 1 | Sep 1, 2024 | Fujian Medical University |
| NCT06158828 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2024 | Rising Tide Foundation, The Leukemia and Lymphoma Society, Washington University in St. Louis |
| NCT06245018 | N/A | Feb 1, 2024 | Nuwacell Biotechnologies Co., Ltd. |
| NCT05990920 | Phase 1 | Aug 23, 2023 | NKGen Biotech, Inc. |
| NCT05987696 | Phase 1 | Aug 10, 2023 | China Academy of Chinese Medical Sciences, Hangzhou Qihan Biotech Co.,Ltd. |
| NCT05976906 | Phase 1 | May 23, 2023 | Zhejiang University |
| NCT05744440 | Early Phase 1 (Phase 1) | Mar 1, 2023 | Xuzhou Medical University |
| NCT05629546 | Phase 1 | Feb 28, 2023 | Washington University in St. Louis |
Organizations
Research & Development (116)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 16 | 14 | 2 | 2006 |
| National Cancer Institute (NCI) | Government | 13 | 4 | 2 | 2006 |
| University of Minnesota | Academic/Hospital | 13 | 12 | 2 | 2005 |
| Jinan University | Academic/Hospital | 10 | 10 | 1 | 2016 |
| Shenzhen Hank Bioengineering Institute | Government | 10 | 0 | 1 | 2016 |
| St. Jude Children's Hospital | Academic/Hospital | 8 | 8 | 3 | 2003 |
| National University of Singapore | Academic/Hospital | 5 | 5 | 2 | 2007 |
| Ohio State University | Academic/Hospital | 5 | 4 | 3 | 2015 |
| Ivy Life Sciences, Co., Ltd | For profit | 4 | 3 | 3 | 2005 |
| University of Ulsan | Academic/Hospital | 4 | 4 | 2 | 2009 |
| Zhejiang University | Academic/Hospital | 4 | 3 | 2 | 2021 |
| Assisi Foundation | Academic/Hospital | 3 | 0 | 2 | 2007 |
| Case Western Reserve University | Academic/Hospital | 3 | 3 | 1 | 2017 |
| Celgene | For profit | 3 | 0 | 2 | 2013 |
| Cornell University | Academic/Hospital | 3 | 3 | 2 | 2007 |
| Government of Taiwan | Government | 3 | 0 | 2 | 2009 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 3 | 0 | 2 | 2014 |
| Universidad Autonoma de Madrid | Academic/Hospital | 3 | 1 | 1 | 2013 |
| University of Washington | Academic/Hospital | 3 | 2 | 1 | 2006 |
| Washington University in St. Louis | Academic/Hospital | 3 | 3 | 2 | 2017 |